XPH News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

XP

AUM

N/A

Volume

150.14K

Yield

0.27%

Chart Earnings News About Dividends Insider Filings

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?The State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed fund offering broad exposure to the pharmaceutical sector with low costs (0.35% expense ratio) and solid year-to-date performance of 12.61%. However, the Healthcare-Pharma sector ranks 11th out of 16 Zacks sectors, and the ETF carries a 'Hold' rating with high risk (beta of 0.61, standard deviation of 20.68%). Investors may also consider alternative pharma ETFs like FTXH and IHE.Zacks Investment Research · Oct 8, 2026

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPHVanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.The Motley Fool · Sep 10, 2026

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH?The article compares two healthcare ETFs: Invesco's IBBQ and State Street's XPH. IBBQ offers lower costs (0.19% expense ratio), broader diversification (253 holdings), and higher dividend yield (0.80%), making it better for long-term investors. XPH delivered stronger 1-year returns (63.90% vs 57.20%) with less volatility but charges higher fees (0.35%) and holds only 65 positions. Both funds have significantly underperformed the S&P 500 over five years, reflecting the challenges of biotech and pharmaceutical investing.The Motley Fool · Jul 8, 2026

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.The Motley Fool · Jul 8, 2026

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?The article compares two healthcare-focused ETFs: State Street SPDR S&P Pharmaceuticals (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers lower costs (0.35% expense ratio vs 0.55%), broader diversification with 59 holdings, and better 1-year performance (38% vs 35.90%), plus dividend income. FBT provides more concentrated biotech exposure with 30 holdings. The analysis concludes XPH is the more appealing long-term choice due to its lower fees and superior performance.The Motley Fool · Jun 4, 2026

Why Is Amneal Pharmaceuticals Stock Gaining Today?Amneal Pharmaceuticals (AMRX) shares rose 3.76% in premarket trading after announcing a definitive agreement to acquire Kashiv BioSciences for $1.1 billion. The acquisition aims to establish Amneal as a fully integrated global biosimilar platform, positioning it to capitalize on a projected $300 billion global biologics loss-of-exclusivity opportunity. The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.Benzinga · Apr 22, 2026

Prestige Bets $1 Billion On World's Most Iconic Nasal StripPrestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion. The acquisition will expand Prestige's consumer health portfolio in sleep and breathing categories and includes other brands like Dimetapp. The deal is expected to close in H1 fiscal 2027 and should boost margins and free cash flow. However, the stock shows technical weakness, trading below its moving averages with negative MACD signals.Benzinga · Mar 20, 2026

Unloved Gilead Due For Reversal On Flight-To-Safety Money FlowsNumerous drugs under development are projected to come to market later this year and next for Gilead. Read why I rate GILD stock a Buy.Seeking Alpha · May 27, 2024

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?Sector ETF report for XPHZacks Investment Research · May 16, 2024

5 Beaten-Down Top-Ranked ETFs to Buy for a TurnaroundWe have highlighted five ETFs from different zones that have plunged the most so far this year but have a solid Zacks ETF Rank.Zacks Investment Research · May 14, 2024

XP

XPHState Street SPDR S&P Pharmaceuticals ETF

XPH

Pay with—

Available Balance0.00

Your PositionYou don't own any XPH yet.

Related Tickers

Earnings

Dividends

Last · Sep 21Quarterly

Amount$0.0420

Yield0.44%

Annual$0.27